骨髓增殖性肿瘤与急性髓系白血病中的多打击TP53突变:142例可评估病例的生存与危险因素比较分析
研究纳入142例伴多打击TP53突变的骨髓增殖性肿瘤或急性髓系白血病患者,比较慢性期、加速期、急变期骨髓增殖性肿瘤与急性髓系白血病的生存。中位随访11.6个月,总生存期在急变期与加速期之间相似,均劣于慢性期;多因素分析中造血干细胞移植和疾病分期或化疗反应与生存改善相关,并发TET2或DNMT3A突变与生存不良相关,并据此构建三层危险模型。
要点
- 多打击TP53突变对骨髓增殖性肿瘤和急性髓系白血病的长期生存均有不利影响。
- 急变期骨髓增殖性肿瘤中位总生存期4.6个月,加速期5.6个月,两者相似。
- 慢性期骨髓增殖性肿瘤中位总生存期11.6个月,与急性髓系白血病7.4个月相似。
核心结论
- 多打击TP53突变对骨髓增殖性肿瘤和急性髓系白血病的长期生存具有同等不利影响,并识别出短期生存的预测因素。
研究设计与样本
- 从梅奥诊所数据库获取142例伴多打击TP53突变的骨髓增殖性肿瘤或急性髓系白血病患者,包括慢性期骨髓增殖性肿瘤19例、加速期骨髓增殖性肿瘤14例、急变期骨髓增殖性肿瘤28例和急性髓系白血病81例。
主要发现
- 中位随访11.6个月,记录到124例(87%)死亡和19例(13%)异基因造血干细胞移植。
- 总生存期从多打击TP53突变检测时计算,急变期骨髓增殖性肿瘤中位4.6个月与加速期5.6个月相似(p=0.5),但两者均劣于慢性期11.6个月(p<0.01)。
- 慢性期骨髓增殖性肿瘤总生存期与急性髓系白血病中位7.4个月相似(p=0.07)。
- 多因素分析中,总生存期受异基因造血干细胞移植有利影响(HR 0.4,p=0.03),受疾病分期(即慢性期疾病)或移植前化疗达到反应有利影响(HR 0.2,p<0.01),受并发TET2突变或DNMT3A突变不利影响(HR 2.7,p<0.01)。
- 基于这些危险因素构建三层危险模型:低危(无危险因素;18例;中位总生存期23.8个月)、中危(一个危险因素;44例;11.1个月)和高危(两个或以上危险因素;80例;4个月;p<0.01)。
关键数值与推荐
- 低危组(无危险因素)18例,中位总生存期23.8个月。
- 中危组(一个危险因素)44例,中位总生存期11.1个月。
- 高危组(两个或以上危险因素)80例,中位总生存期4个月(p<0.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A total of 142 patients with myeloproliferative neoplasms (MPNs) or acute myeloid leukemia (AML) associated with multihit TP53 mutations (mTP53 MUT) were accessed from the Mayo Clinic database and included (i) chronic phase MPN (MPN-CP; N = 19), (ii) accelerated phase MPN (MPN-AP; N = 14), (iii) blast phase MPN (MPN-BP; N = 28), and (iv) AML (N = 81). Concurrent ASXL1 MUT, EZH2 MUT, IDH1,MUT and IDH2 MUT were more common in MPN-MUTBP-mTP53 compared to AML-mTP53 MUT. At median of 11.6 months follow-up, 124 (87%) deaths and 19 (13%) allogeneic stem cell transplantations (ASCT) were documented. Overall survival (OS), calculated from the time of mTP53 MUT detection, was similar between MPN-BP-mTP53 MUT (median 4.6 months) and MPN-AP-mTP53 MUT (5.6 months; p = 0.5) but both were inferior to MPN-CP-mTP53 MUT (11.6 months, p < 0.01). OS in MPN-CP-mTP53 MUT was similar to that of AML-mTP53 MUT (median 7.4 months, p = 0.07). In multivariable analysis, OS was favorably affected by ASCT (HR 0.4, p = 0.03) and disease stage (i.e., chronic phase disease) or achieving response to pre-transplant chemotherapy (HR 0.2, p < 0.01) and unfavorably by the presence of concurrent TET2 MUT or DNMT3A MUT (HR 2.7, p < 0.01). Based on these risk factors, a 3-tiered risk model was constructed: low (no risk factors; N = 18; median OS 23.8 months); intermediate (one risk factor; N = 44; 11.1 months); and high (two or more risk factors; N = 80; 4 months; p < 0.01). The current study highlights the equally detrimental impact of mTP53 MUT on long-term survival in MPN and AML and identifies predictors of short-term survival.
引用
- Fathima S, Abdelmagid M, Alsugair A, et al. Multihit TP53 Mutations in Myeloproliferative Neoplasms and Acute Myeloid Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative Cases. Am J Hematol. 2025. PMID: 40079250. doi:10.1002/ajh.27670
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。